1
|
Pashirova T, Shaihutdinova Z, Tatarinov D, Mansurova M, Kazakova R, Bogdanov A, Chabrière E, Jacquet P, Daudé D, Akhunzianov AA, Miftakhova RR, Masson P. Tuning the Envelope Structure of Enzyme Nanoreactors for In Vivo Detoxification of Organophosphates. Int J Mol Sci 2023; 24:15756. [PMID: 37958742 PMCID: PMC10649860 DOI: 10.3390/ijms242115756] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2023] [Revised: 10/26/2023] [Accepted: 10/26/2023] [Indexed: 11/15/2023] Open
Abstract
Encapsulated phosphotriesterase nanoreactors show their efficacy in the prophylaxis and post-exposure treatment of poisoning by paraoxon. A new enzyme nanoreactor (E-nRs) containing an evolved multiple mutant (L72C/Y97F/Y99F/W263V/I280T) of Saccharolobus solfataricus phosphotriesterase (PTE) for in vivo detoxification of organophosphorous compounds (OP) was made. A comparison of nanoreactors made of three- and di-block copolymers was carried out. Two types of morphology nanoreactors made of di-block copolymers were prepared and characterized as spherical micelles and polymersomes with sizes of 40 nm and 100 nm, respectively. The polymer concentrations were varied from 0.1 to 0.5% (w/w) and enzyme concentrations were varied from 2.5 to 12.5 μM. In vivo experiments using E-nRs of diameter 106 nm, polydispersity 0.17, zeta-potential -8.3 mV, and loading capacity 15% showed that the detoxification efficacy against paraoxon was improved: the LD50 shift was 23.7xLD50 for prophylaxis and 8xLD50 for post-exposure treatment without behavioral alteration or functional physiological changes up to one month after injection. The pharmacokinetic profiles of i.v.-injected E-nRs made of three- and di-block copolymers were similar to the profiles of the injected free enzyme, suggesting partial enzyme encapsulation. Indeed, ELISA and Western blot analyses showed that animals developed an immune response against the enzyme. However, animals that received several injections did not develop iatrogenic symptoms.
Collapse
Affiliation(s)
- Tatiana Pashirova
- Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Arbuzov Str., 8, 420088 Kazan, Russia; (Z.S.); (D.T.); (A.B.)
| | - Zukhra Shaihutdinova
- Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Arbuzov Str., 8, 420088 Kazan, Russia; (Z.S.); (D.T.); (A.B.)
- Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia; (M.M.); (R.K.); (A.A.A.); (R.R.M.)
| | - Dmitry Tatarinov
- Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Arbuzov Str., 8, 420088 Kazan, Russia; (Z.S.); (D.T.); (A.B.)
| | - Milana Mansurova
- Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia; (M.M.); (R.K.); (A.A.A.); (R.R.M.)
| | - Renata Kazakova
- Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia; (M.M.); (R.K.); (A.A.A.); (R.R.M.)
| | - Andrei Bogdanov
- Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Arbuzov Str., 8, 420088 Kazan, Russia; (Z.S.); (D.T.); (A.B.)
| | - Eric Chabrière
- Gene&GreenTK, 19–21 Boulevard Jean Moulin, 13005 Marseille, France; (E.C.); (P.J.); (D.D.)
- IRD, APHM, MEPHI, IHU-Méditerranée Infection, Aix Marseille Université, 19–21 Boulevard Jean Moulin, 13005 Marseille, France
| | - Pauline Jacquet
- Gene&GreenTK, 19–21 Boulevard Jean Moulin, 13005 Marseille, France; (E.C.); (P.J.); (D.D.)
| | - David Daudé
- Gene&GreenTK, 19–21 Boulevard Jean Moulin, 13005 Marseille, France; (E.C.); (P.J.); (D.D.)
| | - Almaz A. Akhunzianov
- Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia; (M.M.); (R.K.); (A.A.A.); (R.R.M.)
| | - Regina R. Miftakhova
- Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia; (M.M.); (R.K.); (A.A.A.); (R.R.M.)
| | - Patrick Masson
- Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia; (M.M.); (R.K.); (A.A.A.); (R.R.M.)
| |
Collapse
|
2
|
Cusi MG, Di Giacomo AM, Anichini G, Gori Savellini G, Terrosi C, Gandolfo C, Maio M. Rational Use of Monoclonal Antibodies as Therapeutic Treatment in an Oncologic Patient with Long COVID. Viruses 2023; 15:v15030614. [PMID: 36992322 PMCID: PMC10052532 DOI: 10.3390/v15030614] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2023] [Revised: 02/10/2023] [Accepted: 02/22/2023] [Indexed: 03/31/2023] Open
Abstract
We present the case of a 76-year-old male patient persistently infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the setting of a stage IIIC cutaneous melanoma and non-Hodgkin's lymphoma (NHL). Due to the persistent coronavirus disease 19 (COVID-19), all cancer treatments were discontinued. Because of the worsening of his clinical state and the persistence of SARS-CoV-2 positivity for more than six months, the patient was treated with sotrovimab, which was ineffective due to resistance mutations acquired during that time. In order to resume cancer treatment and make the patient free from SARS-CoV-2, an in vitro screening of Evusheld monoclonal antibodies (tixagevumab-cilgavimab) against the viral strains isolated from the subject was performed. The promising results obtained during in vitro testing led to the authorization of the off-label use of Evusheld, which made the patient negative for SARS-CoV-2, thus, allowing him to resume his cancer treatment. This study highlights the Evusheld monoclonal antibodies' efficacy, not only in prevention but also in successful therapy against prolonged COVID-19. Therefore, testing neutralizing monoclonal antibodies in vitro against SARS-CoV-2 mutants directly isolated from patients could provide useful information for the treatment of people affected by long COVID.
Collapse
Affiliation(s)
- Maria Grazia Cusi
- Virology Unit, Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy
- Virology Unit, Department of Medical Biotechnolopgies, Santa Maria Alle Scotte University Hospital, V.le Bracci 16, 53100 Siena, Italy
| | - Anna Maria Di Giacomo
- Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Medical Sciences, Surgical and Neuroscience, 53100 Siena, Italy
- Italian Network for Tumor Bio-Immunotherapy Foundation Onlus, 53100 Siena, Italy
| | - Gabriele Anichini
- Virology Unit, Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy
| | - Gianni Gori Savellini
- Virology Unit, Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy
| | - Chiara Terrosi
- Virology Unit, Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy
| | - Claudia Gandolfo
- Virology Unit, Department of Medical Biotechnolopgies, Santa Maria Alle Scotte University Hospital, V.le Bracci 16, 53100 Siena, Italy
| | - Michele Maio
- Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Medical Sciences, Surgical and Neuroscience, 53100 Siena, Italy
- Italian Network for Tumor Bio-Immunotherapy Foundation Onlus, 53100 Siena, Italy
| |
Collapse
|
3
|
Pashirova T, Shaihutdinova Z, Mansurova M, Kazakova R, Shambazova D, Bogdanov A, Tatarinov D, Daudé D, Jacquet P, Chabrière E, Masson P. Enzyme Nanoreactor for In Vivo Detoxification of Organophosphates. ACS Appl Mater Interfaces 2022; 14:19241-19252. [PMID: 35440137 DOI: 10.1021/acsami.2c03210] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
A nanoreactor containing an evolved mutant of Saccharolobus solfataricus phosphotriesterase (L72C/Y97F/Y99F/W263V/I280T) as a catalytic bioscavenger was made for detoxification of organophosphates. This nanoreactor intended for treatment of organophosphate poisoning was studied against paraoxon (POX). Nanoreactors were low polydispersity polymersomes containing a high concentration of enzyme (20 μM). The polyethylene glycol-polypropylene sulfide membrane allowed for penetration of POX and exit of hydrolysis products. In vitro simulations under second order conditions showed that 1 μM enzyme inactivates 5 μM POX in less than 10 s. LD50-shift experiments of POX-challenged mice through intraperitoneal (i.p.) and subcutaneous (s.c.) injections showed that intravenous administration of nanoreactors (1.6 nmol enzyme) protected against 7 × LD50 i.p. in prophylaxis and 3.3 × LD50 i.p. in post-exposure treatment. For mice s.c.-challenged, LD50 shifts were more pronounced: 16.6 × LD50 in prophylaxis and 9.8 × LD50 in post-exposure treatment. Rotarod tests showed that transitory impaired neuromuscular functions of challenged mice were restored the day of experiments. No deterioration was observed in the following days and weeks. The high therapeutic index provided by prophylactic administration of enzyme nanoreactors suggests that no other drugs are needed for protection against acute POX toxicity. For post-exposure treatment, co-administration of classical drugs would certainly have beneficial effects against transient incapacitation.
Collapse
Affiliation(s)
- Tatiana Pashirova
- Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Arbuzov Str., 8, Kazan 420088, Russian Federation
| | - Zukhra Shaihutdinova
- Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Arbuzov Str., 8, Kazan 420088, Russian Federation
- Biochemical Neuropharmacology Laboratory, Kazan Federal University, Kremlevskaya Str., 18, Kazan 420111, Russian Federation
| | - Milana Mansurova
- Biochemical Neuropharmacology Laboratory, Kazan Federal University, Kremlevskaya Str., 18, Kazan 420111, Russian Federation
| | - Renata Kazakova
- Biochemical Neuropharmacology Laboratory, Kazan Federal University, Kremlevskaya Str., 18, Kazan 420111, Russian Federation
| | - Dinara Shambazova
- Biochemical Neuropharmacology Laboratory, Kazan Federal University, Kremlevskaya Str., 18, Kazan 420111, Russian Federation
| | - Andrei Bogdanov
- Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Arbuzov Str., 8, Kazan 420088, Russian Federation
| | - Dmitry Tatarinov
- Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Arbuzov Str., 8, Kazan 420088, Russian Federation
| | - David Daudé
- Gene&GreenTK, 19-21 Boulevard Jean Moulin, Marseille 13005, France
| | - Pauline Jacquet
- Gene&GreenTK, 19-21 Boulevard Jean Moulin, Marseille 13005, France
| | - Eric Chabrière
- Gene&GreenTK, 19-21 Boulevard Jean Moulin, Marseille 13005, France
- Aix Marseille University, IRD, APHM, MEPHI, IHU-Méditerranée Infection, 19-21 Boulevard Jean Moulin, Marseille 13005, France
| | - Patrick Masson
- Biochemical Neuropharmacology Laboratory, Kazan Federal University, Kremlevskaya Str., 18, Kazan 420111, Russian Federation
| |
Collapse
|
4
|
Abstract
The objective of this study was to identify factors that determine medical treatment seeking behaviour following potential rabies exposure after being bitten by a suspected dog and the likelihood of compliance to receive sufficient doses of post-exposure prophylaxis after the visit to a health centre visit. A detailed survey based on case investigation was conducted on suspected rabid dog bite cases in three areas of Ethiopia. Two multivariable logistic regression models were created with a set of putative variables to explain treatment seeking and compliance outcomes. Based on the registered bite cases at each health centre and the set of unregistered bite cases derived by contact tracing, 655 bite victim cases were identified to have occurred between September 2013 and August 2014. Of these evaluated bite incidences, 465 cases were considered to have been caused by a potentially rabid dog. About 77% of these suspected rabid dog bite victims visited a health centre, while 57% received sufficient doses of PEP. The overall likelihood of seeking medical services following rabies exposure was higher for people bitten by dogs of unknown ownership, where the bite was severe, being bitten on the leg, spend of more than 100 USD per month and where the victim lived close to the nearest health centre, while the likelihood of receiving sufficient doses of PEP was sensitive to monthly spending and distance to health centre. However, the evaluated factors did only explain a part of the variation among the three districts. The district in which victims lived appeared to have a relevant influence on the likelihood of seeking medical treatment but did not improve the prediction on the likelihood of treatment compliance. Given the insights obtained from this study, improvements in the rural districts with regard to accessibility of post-exposure prophylaxis delivering health centres in shorter distance could improve health seeking behaviour. In addition, in rural districts, majority of exposed persons who seek medical treatment tend to comply with treatment regimen, indicating that the promotion of medical treatment through awareness creation campaigns could be beneficial.
Collapse
Affiliation(s)
- T J Beyene
- Business Economics Group, Wageningen University, Wageningen, The Netherlands.,College of Veterinary Medicine and Agriculture, Addis Ababa University, Addis Ababa, Ethiopia.,Center for Outcome Research and Epidemiology, Department of Diagnostic Medicine and Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS, USA
| | - M C M Mourits
- Business Economics Group, Wageningen University, Wageningen, The Netherlands
| | - C W Revie
- Centre for Veterinary Epidemiological Research, Atlantic Veterinary College, University of Prince Edward Island, Charlottetown, PE, Canada
| | - H Hogeveen
- Business Economics Group, Wageningen University, Wageningen, The Netherlands.,Department Farm Animal Health, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands
| |
Collapse
|
5
|
Masson P, Nachon F. Cholinesterase reactivators and bioscavengers for pre- and post-exposure treatments of organophosphorus poisoning. J Neurochem 2017; 142 Suppl 2:26-40. [PMID: 28542985 DOI: 10.1111/jnc.14026] [Citation(s) in RCA: 70] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2016] [Revised: 03/02/2017] [Accepted: 03/10/2017] [Indexed: 12/11/2022]
Abstract
Organophosphorus agents (OPs) irreversibly inhibit acetylcholinesterase (AChE) causing a major cholinergic syndrome. The medical counter-measures of OP poisoning have not evolved for the last 30 years with carbamates for pretreatment, pyridinium oximes-based AChE reactivators, antimuscarinic drugs and neuroprotective benzodiazepines for post-exposure treatment. These drugs ensure protection of peripheral nervous system and mitigate acute effects of OP lethal doses. However, they have significant limitations. Pyridostigmine and oximes do not protect/reactivate central AChE. Oximes poorly reactivate AChE inhibited by phosphoramidates. In addition, current neuroprotectants do not protect the central nervous system shortly after the onset of seizures when brain damage becomes irreversible. New therapeutic approaches for pre- and post-exposure treatments involve detoxification of OP molecules before they reach their molecular targets by administrating catalytic bioscavengers, among them phosphotriesterases are the most promising. Novel generation of broad spectrum reactivators are designed for crossing the blood-brain barrier and reactivate central AChE. This is an article for the special issue XVth International Symposium on Cholinergic Mechanisms.
Collapse
Affiliation(s)
- Patrick Masson
- Neuropharmacology Laboratory, Kazan Federal University, Kazan, Russia
| | - Florian Nachon
- Institut de Recherche Biomédicale des Armées, Brétigny-sur-Orge, Cédex, France
| |
Collapse
|